Literature DB >> 10688814

Interleukin 5 regulates the isoform expression of its own receptor alpha-subunit.

J Tavernier1, J Van der Heyden, A Verhee, G Brusselle, X Van Ostade, J Vandekerckhove, J North, S M Rankin, A B Kay, D S Robinson.   

Abstract

The receptor for interleukin 5 (IL-5) consists of a cytokine-specific alpha chain (IL-5Ralpha) and a signaling beta chain, which is shared with interleukin 3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF). These 3 cytokines can act in eosinophil development and activation in vitro, but gene deletion or antibody blocking of IL-5 largely ablates eosinophilic responses in models of allergic disease or helminth infection. We investigated factors acting in differential IL-5Ralpha gene splicing to generate either the membrane-anchored isoform (TM-IL-5Ralpha) which associates with the common beta chain to allow IL-5 responsiveness, or a secreted, antagonist variant (SOL-IL-5Ralpha). In a murine myeloid cell line (FDC-P1), transfected with minigenes allowing expression of either IL-5Ralpha variant, IL-5 itself, but not IL-3 or GM-CSF, stimulated a reversible switch toward expression of TM-IL-5Ralpha. A switch from predominantly soluble isoform to TM-IL-5Ralpha messenger RNA (mRNA) expression was also seen during IL-5-driven eosinophil development from human umbilical cord blood-derived CD34(+) cells; this was accompanied by surface expression of IL-5Ralpha and acquisition of functional responses to IL-5. IL-3 and GM-CSF also supported eosinophil development and up-regulation of TM-IL-5Ralpha mRNA in this system, but this was preceded by expression of IL-5 mRNA and was inhibited by monoclonal antibody to IL-5. These data suggest IL-5-specific signaling, not shared by IL-3 and GM-CSF, leading to a switch toward up-regulation of functional IL-5Ralpha and, furthermore, that IL-3 and GM-CSF-driven eosinophil development is dependent on IL-5, providing an explanation for the selective requirement of IL-5 for expansion of the eosinophil lineage. (Blood. 2000;95:1600-1607)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688814

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Proteasomal regulation of betac signaling reveals a novel mechanism for cytokine receptor heterotypic desensitization.

Authors:  M Martinez-Moczygemba; D P Huston
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 2.  In situ hematopoiesis: a regulator of TH2 cytokine-mediated immunity and inflammation at mucosal surfaces.

Authors:  C C K Hui; K M McNagny; J A Denburg; M C Siracusa
Journal:  Mucosal Immunol       Date:  2015-03-18       Impact factor: 7.313

3.  Schistosoma mansoni infection in eosinophil lineage-ablated mice.

Authors:  Jonathan M Swartz; Kimberly D Dyer; Allen W Cheever; Thirumalai Ramalingam; Lesley Pesnicak; Joseph B Domachowske; James J Lee; Nancy A Lee; Paul S Foster; Thomas A Wynn; Helene F Rosenberg
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

4.  IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis.

Authors:  Todd M Wilson; Irina Maric; Juhi Shukla; Margaret Brown; Carlo Santos; Olga Simakova; Paneez Khoury; Michael P Fay; Alexander Kozhich; Roland Kolbeck; Dean D Metcalfe; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2011-07-16       Impact factor: 10.793

5.  Interleukin-5 in growth and differentiation of blood eosinophil progenitors in asthma: effect of glucocorticoids.

Authors:  H P Kuo; C H Wang; H C Lin; K S Hwang; S L Liu; K F Chung
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  PTP1B deficiency exacerbates inflammation and accelerates leukocyte trafficking in vivo.

Authors:  Sergejs Berdnikovs; Vladimir I Pavlov; Hiam Abdala-Valencia; Christine A McCary; David J Klumpp; Michel L Tremblay; Joan M Cook-Mills
Journal:  J Immunol       Date:  2011-12-09       Impact factor: 5.422

Review 7.  Essential Mechanisms of Differential Activation of Eosinophils by IL-3 Compared to GM-CSF and IL-5.

Authors:  Stephane Esnault; Elizabeth A Kelly
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

8.  Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.

Authors:  Miguel L Stein; Joyce M Villanueva; Bridget K Buckmeier; Yoshiyuki Yamada; Alexandra H Filipovich; Amal H Assa'ad; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2008-04-14       Impact factor: 10.793

9.  Regulation of the interleukin-5 receptor alpha-subunit on peripheral blood eosinophils from healthy subjects.

Authors:  C Hellman; G Halldén; B Hylander; J Lundahl
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

Review 10.  Eosinophils in the pathogenesis of allergic airways disease.

Authors:  S G Trivedi; C M Lloyd
Journal:  Cell Mol Life Sci       Date:  2007-05       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.